Nicole Payne
Family · Southaven, MSNPI 1851575138
Payments from drug & device makers
Across 431 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- AstraZeneca$747
- Johnson & Johnson$556
- Esperion Therapeutics, Inc.$377
- plus $2K from 32 others
What the payments were for
- Food & beverage$8,125100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 112 | $1,482 |
| Novo Nordisk | 75 | $1,343 |
| Lilly USA, LLC | 79 | $1,315 |
| AstraZeneca | 25 | $747 |
| Johnson & Johnson | 8 | $556 |
| Esperion Therapeutics, Inc. | 6 | $377 |
| Boehringer Ingelheim | 15 | $224 |
| Pfizer | 12 | $199 |
| Amarin Pharma, Inc. | 13 | $199 |
| Phathom Pharmaceuticals, Inc. | 6 | $155 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $147 |
| Bayer | 7 | $127 |
| Paratek Pharmaceuticals, Inc. | 1 | $125 |
| Amgen | 7 | $117 |
| Abbott | 5 | $115 |
| GSK | 7 | $93 |
| Boston Scientific | 3 | $85 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $78 |
| Astellas Pharma US Inc | 5 | $73 |
| Merck | 4 | $62 |
| Dexcom, Inc. | 2 | $45 |
| Shield Therapeutics Inc | 3 | $45 |
| Abiomed | 1 | $42 |
| Electromed, Inc. | 2 | $37 |
| Biohaven Pharmaceuticals, Inc. | 3 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Edwards Lifesciences | 1 | $24 |
| Heartflow, Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Tris Pharma Inc | 1 | $17 |
| Seqirus USA Inc | 1 | $16 |
| Novartis | 1 | $16 |
| Bausch Health US, LLC | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Nevro Corp. | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Impel Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,125 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 47 | $64,814 |
| MounjaroTirzepatide | 50 | $54,037 |
| JardianceEmpagliflozin | 45 | $46,978 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $24,019 |
| EliquisApixaban | 25 | $19,974 |
| FarxigaDapagliflozin Propanediol | 16 | $18,097 |
| XareltoRivaroxaban | 21 | $17,229 |
| JanuviaSitagliptin Phosphate | 17 | $15,085 |
| TrulicityDulaglutide | 12 | $12,094 |
| SynthroidLevothyroxine Sodium | 63 | $6,233 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $4,480 |
| Ezetimibe | 103 | $4,161 |
| Rosuvastatin Calcium | 280 | $3,653 |
| Atorvastatin Calcium | 205 | $1,697 |
| Levothyroxine Sodium | 153 | $1,507 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,315 | $66,13162 claims |
| Novo NordiskOzempic | $1,343 | $64,81447 claims |
| Boehringer IngelheimJardiance | $224 | $46,97845 claims |
| GSKTrelegy Ellipta | $93 | $24,01922 claims |
| AstraZenecaFarxiga, Symbicort | $747 | $22,57727 claims |
| PfizerEliquis | $199 | $19,97425 claims |
| Johnson & JohnsonXarelto | $556 | $17,22921 claims |
| MerckJanuvia | $62 | $15,08517 claims |
| AbbVieSynthroid | $1,482 | $6,23363 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.
Other family in Southaven
- Lindsey GarnerSouthaven$16K
- Angela UgwuanyiSouthaven$13K
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.